# PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

> **NCT05390892** · PHASE4 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 6000 (estimated)

## Conditions studied

- Type2Diabetes
- ASCVD

## Interventions

- **DRUG:** SGLT2 inhibitor
- **DRUG:** GLP-1 receptor agonist

## Key facts

- **NCT ID:** NCT05390892
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-26
- **Primary completion:** 2029-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05390892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05390892, "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05390892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*